Table 3. Characteristics of patients included in treatment success analysis.
| Total | Patients with TDR∧receiving fully activecART | Patients withTDR∧receiving non-fullyactive cART | Patientswithout TDR∧ | p-value | |
| Patients of sample (%) | 323 (100) | 41 (12.7) | 18 (5,6) | 264 (81.7) | |
| Sex | 0.331 | ||||
| men (%) | 311 (96.3) | 38 (92,7) | 18 (100) | 255 (95.7) | |
| women (%) | 12 (3.7) | 3 (7,3) | 0 | 9 (4.3) | |
| Median age at sca (IQR)* | 35 (29–40) | 37 (29–43) | 33 (29–38) | 34 (29–40) | 0.43 |
| Transmission group | |||||
| MSM° (%) | 292 (90.4) | 34 (82.9) | 16 (88.8) | 242 (91.7) | 0.201 |
| Heterosexual contacts | 23 (7.1) | 6 (14.6) | 1 (5.6) | 16 (6.0) | 0.131 |
| High prevalence country | 1 (0.3) | 0 | 0 | 1 (0.4) | 0.891 |
| Intravenous drug use | 1 (0.3) | 1 (2.5) | 0 | 0 | 0,031 |
| Unknown | 20 (1.2) | 0 | 1 (5.6) | 5 (1.9) | 0.351 |
| Median time to FL-ART = (day) (CI”) | 632 (559–684) | 757 (557–1,014) | 550 (244–800) | 613 (530–666) | |
| Univariable HR3 for time to FL-ART = (p-value) | 0.87 (0.43) | 1.38 (0.19) | 1.00 | ||
| Multivariable HR for time to FL-ART = (p-value) | 0.87 (0.42) | 1.44 (0.14) | 1.00 | ||
| Median VL× at start of FL-ART = (log/ml) (IQR*) | 5.3 (4.5–5.9) | 5.23 (4.5–5.6) | 4.59 (4.3–5.5) | 4.95 (4.5–5.4) | 0.422 |
| Median CD4 cc∼ at start of FL-ART = (cells/µl)(IQR*) (n) | 277 (200–380) | 270 (210–358) | 350.5 (290–488) | 272 (194.5–377.5) | 0.022 |
| Median duration of FL-ART = (day) (CI”) | 1,919 (1,542–*) | 1,400 (916–*) | 1,681 (575–2,112) | 2,386 (1,542–*) | |
| Univariable HR for duration of FL-ART = (p-value) | 1.12 (0.72) | 1.29 (0.52) | 1.00 | ||
| Multivariable HR for duration of FL-ART = (p-value) | 1.16 (0.63) | 1.3 (0.48) | 1.00 | ||
| Pat. with treatment success (2 cons. VL×<500 copies/ml) (%) | 310 (96.0) | 43 (93.5) | 17 (94.4) | 256 (96.4) | |
| Pat. with virologic failure (min. 1 VL×>500 copies/ml) (%) | 13 (4.0) | 3 (6.5) | 1 (5.6) | 9 (3.4) | 0.471 |
| Univariable odds ratio to compare virologicalfailure (p-value) | 2.24 (0.24) | 1.67 (0.64) | 1.00 | ||
| Multivariable odds ratio to compare virologicalfailure (p-value) | 2.34 (0.22) | 1.78 (0.60) | 1.00 | ||
| Pat. with blip (transient VL× <1,000 und>500 copies/ml) (%) | 2 (0.6) | 0 | 0 | 2 (0.8) |
a sc: seroconversion.
1 chi-square test.
2 Kruskal-wallis test.
3 HR: hazard ratio.
° MSM: men who have sex with men.
∧ TDR: transmitted drug resistance according to Stanford algorithm.
* IQR: interquartile range.
“ CI: 95% confidence interval.
∼ cc: cell count.
×
VL: Viral load.
=
FL-ART: first-line AR.